vs

Side-by-side financial comparison of CREATIVE REALITIES, INC. (CREX) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

CREATIVE REALITIES, INC. is the larger business by last-quarter revenue ($23.9M vs $12.5M, roughly 1.9× Avidity Biosciences, Inc.). CREATIVE REALITIES, INC. runs the higher net margin — -8.2% vs -1398.3%, a 1390.1% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 117.2%). CREATIVE REALITIES, INC. produced more free cash flow last quarter ($-4.6M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 39.5%).

Creative Realities, Inc. is a provider of end-to-end immersive digital experience solutions, including interactive digital signage, content management software, and custom experiential design services. It primarily caters to retail, hospitality, healthcare, corporate workplace, and public sector clients across North America, helping brands enhance customer engagement and operational efficiency.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

CREX vs RNA — Head-to-Head

Bigger by revenue
CREX
CREX
1.9× larger
CREX
$23.9M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+316.8% gap
RNA
434.0%
117.2%
CREX
Higher net margin
CREX
CREX
1390.1% more per $
CREX
-8.2%
-1398.3%
RNA
More free cash flow
CREX
CREX
$152.3M more FCF
CREX
$-4.6M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
39.5%
CREX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CREX
CREX
RNA
RNA
Revenue
$23.9M
$12.5M
Net Profit
$-2.0M
$-174.4M
Gross Margin
47.9%
Operating Margin
1.9%
-1513.5%
Net Margin
-8.2%
-1398.3%
Revenue YoY
117.2%
434.0%
Net Profit YoY
30.8%
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CREX
CREX
RNA
RNA
Q4 25
$23.9M
Q3 25
$10.5M
$12.5M
Q2 25
$13.0M
$3.8M
Q1 25
$9.7M
$1.6M
Q4 24
$11.0M
$3.0M
Q3 24
$14.4M
$2.3M
Q2 24
$13.1M
$2.0M
Q1 24
$12.3M
$3.5M
Net Profit
CREX
CREX
RNA
RNA
Q4 25
$-2.0M
Q3 25
$-7.9M
$-174.4M
Q2 25
$-1.8M
$-157.3M
Q1 25
$3.4M
$-115.8M
Q4 24
$-2.8M
$-102.3M
Q3 24
$54.0K
$-80.4M
Q2 24
$-615.0K
$-70.8M
Q1 24
$-109.0K
$-68.9M
Gross Margin
CREX
CREX
RNA
RNA
Q4 25
47.9%
Q3 25
45.3%
Q2 25
38.5%
Q1 25
45.7%
Q4 24
44.2%
Q3 24
45.6%
Q2 24
51.8%
Q1 24
46.9%
Operating Margin
CREX
CREX
RNA
RNA
Q4 25
1.9%
Q3 25
-68.9%
-1513.5%
Q2 25
-10.2%
-4448.7%
Q1 25
-7.4%
-8360.9%
Q4 24
-6.5%
-4069.6%
Q3 24
7.9%
-4200.9%
Q2 24
4.5%
-4040.4%
Q1 24
-0.6%
-2178.6%
Net Margin
CREX
CREX
RNA
RNA
Q4 25
-8.2%
Q3 25
-74.5%
-1398.3%
Q2 25
-13.9%
-4089.3%
Q1 25
34.6%
-7360.0%
Q4 24
-25.8%
-3439.5%
Q3 24
0.4%
-3441.7%
Q2 24
-4.7%
-3461.8%
Q1 24
-0.9%
-1943.4%
EPS (diluted)
CREX
CREX
RNA
RNA
Q4 25
Q3 25
$-0.75
$-1.27
Q2 25
$-0.17
$-1.21
Q1 25
$0.32
$-0.90
Q4 24
$-0.28
$-0.80
Q3 24
$0.01
$-0.65
Q2 24
$-0.06
$-0.65
Q1 24
$-0.01
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CREX
CREX
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$1.6M
$350.2M
Total DebtLower is stronger
$44.0M
Stockholders' EquityBook value
$21.5M
$1.9B
Total Assets
$151.0M
$2.1B
Debt / EquityLower = less leverage
2.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CREX
CREX
RNA
RNA
Q4 25
$1.6M
Q3 25
$314.0K
$350.2M
Q2 25
$569.0K
$243.9M
Q1 25
$1.1M
$254.2M
Q4 24
$1.0M
$219.9M
Q3 24
$868.0K
$370.2M
Q2 24
$4.1M
$575.8M
Q1 24
$2.9M
$471.4M
Total Debt
CREX
CREX
RNA
RNA
Q4 25
$44.0M
Q3 25
$22.0M
Q2 25
$19.9M
Q1 25
$23.0M
Q4 24
$13.0M
Q3 24
$10.7M
Q2 24
$13.6M
Q1 24
$12.8M
Stockholders' Equity
CREX
CREX
RNA
RNA
Q4 25
$21.5M
Q3 25
$21.9M
$1.9B
Q2 25
$29.4M
$1.2B
Q1 25
$29.9M
$1.3B
Q4 24
$25.5M
$1.4B
Q3 24
$28.3M
$1.5B
Q2 24
$28.2M
$1.2B
Q1 24
$28.8M
$830.9M
Total Assets
CREX
CREX
RNA
RNA
Q4 25
$151.0M
Q3 25
$61.3M
$2.1B
Q2 25
$63.7M
$1.4B
Q1 25
$67.0M
$1.5B
Q4 24
$65.2M
$1.6B
Q3 24
$67.6M
$1.6B
Q2 24
$69.6M
$1.3B
Q1 24
$68.2M
$951.5M
Debt / Equity
CREX
CREX
RNA
RNA
Q4 25
2.04×
Q3 25
1.00×
Q2 25
0.68×
Q1 25
0.77×
Q4 24
0.51×
Q3 24
0.38×
Q2 24
0.48×
Q1 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CREX
CREX
RNA
RNA
Operating Cash FlowLast quarter
$-4.5M
$-156.2M
Free Cash FlowOCF − Capex
$-4.6M
$-156.9M
FCF MarginFCF / Revenue
-19.1%
-1257.6%
Capex IntensityCapex / Revenue
0.4%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.1M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CREX
CREX
RNA
RNA
Q4 25
$-4.5M
Q3 25
$-1.6M
$-156.2M
Q2 25
$773.0K
$-199.7M
Q1 25
$-2.4M
$-124.8M
Q4 24
$-1.4M
$-99.9M
Q3 24
$544.0K
$-65.6M
Q2 24
$2.3M
$-65.0M
Q1 24
$1.9M
$-70.4M
Free Cash Flow
CREX
CREX
RNA
RNA
Q4 25
$-4.6M
Q3 25
$-1.7M
$-156.9M
Q2 25
$672.0K
$-203.0M
Q1 25
$-2.5M
$-128.6M
Q4 24
$-1.4M
$-103.8M
Q3 24
$543.0K
$-67.3M
Q2 24
$2.3M
$-65.5M
Q1 24
$1.9M
$-71.3M
FCF Margin
CREX
CREX
RNA
RNA
Q4 25
-19.1%
Q3 25
-16.2%
-1257.6%
Q2 25
5.2%
-5277.1%
Q1 25
-25.2%
-8174.3%
Q4 24
-12.5%
-3491.0%
Q3 24
3.8%
-2881.8%
Q2 24
17.3%
-3204.6%
Q1 24
15.7%
-2012.3%
Capex Intensity
CREX
CREX
RNA
RNA
Q4 25
0.4%
Q3 25
1.0%
5.7%
Q2 25
0.8%
86.9%
Q1 25
0.1%
238.6%
Q4 24
0.0%
131.7%
Q3 24
0.0%
72.9%
Q2 24
0.0%
26.0%
Q1 24
0.0%
25.8%
Cash Conversion
CREX
CREX
RNA
RNA
Q4 25
Q3 25
Q2 25
Q1 25
-0.73×
Q4 24
Q3 24
10.07×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CREX
CREX

Service And Other$17.3M72%
Managed Services$4.7M20%
Installation Services$1.7M7%

RNA
RNA

Segment breakdown not available.

Related Comparisons